# Sofinnova Investments: portfolio, investments and team

> Sofinnova Investments is a vc firm based in United States. 161 investments on record, 2 in the last 12 months, latest Oct 2026.

Source: https://millionrounds.com/fund/sofinnova-investments (Millionrounds; every figure on the page links to its filing or article)

United States · [Investor](https://millionrounds.com/investors)

# Sofinnova Investments

Last cheque observed Oct 2026; 161 cheques on record.

Email

Deploying now New fund $500M, Aug 2025 VC firm

Growth Pre-seed Seed Collaboration Consumer Education

Follow Sofinnova Investments and see its new cheques in your feed. [Start following](https://millionrounds.com/login?join=1&why=follow&next=%2Ffund%2Fsofinnova-investments)

Deploying now

**100%** of best year **2** **cheques in 12 months**, 161 on record

Since the last cheque **8** days **00** hrs **00** min **00** sec

Median round **$39M** Rounds led **2 of 161** Sole investor **9 rounds** Exits **28 from the portfolio** Mostly in **United States, 79%**

Pitch Sofinnova Investments

## Sofinnova Investments highlights

- 01 2 cheques in the last 12 months
- 02 Mostly Series B and Series A: 52% of its rounds
- 03 Sole investor in 9 rounds, median $14M
- 04 28 exits from the portfolio

## What they do

> No descriptive text about Sofinnova Investments was found in the provided homepage text. From their own website

- **Type:** VC firm
- **Cheque size:** Not stated
- **Stages:** Growth Pre-seed Seed Series A Series B
- **Sectors:** Collaboration Consumer Education
- **Based in:** Menlo Park, United States
- **Cold pitches:** Not stated

## The record

Every round we can evidence, newest first **161 appearances**

- **2026** 2 rounds
- **Oct** **[Star Therapeutics](https://millionrounds.com/company/star-therapeutics)** US · Pulse 2.0 **$200M** With 10 others
- **Jun** **[City Therapeutics](https://millionrounds.com/company/city-therapeutics)** Series B · US · Ventureburn **$100M** *Led*
- **2025** 1 round
- **Apr** **[Atsena Therapeutics](https://millionrounds.com/company/atsena-therapeutics)** Series C · US · Hatteras Venture Partners **$150M** With 9 others
- **2024** 1 round
- **Mar** **[Capstan Therapeutics](https://millionrounds.com/company/capstan-therapeutics)** Series B · US · Firms' own news pages **$175M** With 15 others
- **2019** 4 rounds
- **Oct** **[Intrepida Bio](https://millionrounds.com/company/intrepida-bio)** Series A · US · FinSMEs **$9.5M** With 3 others
- **May** **[DNA Script](https://millionrounds.com/company/dna-script)** Series B · FR · FinSMEs **$39M** With 6 others
- **Apr** **[Inozyme Pharma](https://millionrounds.com/company/inozyme-pharma)** Series A · US · FinSMEs **$67M** With 8 others
- **Apr** **[Karuna](https://millionrounds.com/company/karuna)** US · FinSMEs **$12M** Sole investor
- **2018** 12 rounds
- **Dec** **[XyloCor](https://millionrounds.com/company/xylocor)** Series A · US · Medcitynews **$17M** *Led*
- **Nov** **[NextCure](https://millionrounds.com/company/nextcure)** Series B · MD · Pehub **$93M** With 12 others
- **Oct** **[Rgenix](https://millionrounds.com/company/rgenix)** Series C · US · FinSMEs **$40M** With 4 others
- **Aug** **[Akuous](https://millionrounds.com/company/akuous)** Series A · US · FinSMEs **$50M** With 4 others
- **Jul** **[HotSpot Therapeutics](https://millionrounds.com/company/hotspot-therapeutics)** Series A · US · FinSMEs **$45M** With 1 other
- **Jul** **[Antiva](https://millionrounds.com/company/antiva)** Series C · US · FinSMEs **$15M** With 5 others
- **Jun** **[Enyo Pharma](https://millionrounds.com/company/enyo-pharma)** Series B · FR · FinSMEs **$47M** With 5 others
- **May** **[BioClin](https://millionrounds.com/company/bioclin)** Series B · FinSMEs **$20M** With 6 others
- **Apr** **[Crescendo](https://millionrounds.com/company/crescendo)** Series B · GB · FinSMEs **$70M** With 5 others
- **Apr** **[Corvidia](https://millionrounds.com/company/corvidia)** Series B · US · FinSMEs **$60M** With 8 others
- **Apr** **[RefleXion](https://millionrounds.com/company/reflexion)** Series C · US · FinSMEs **$100M** With 6 others
- **Jan** **[Aledia](https://millionrounds.com/company/aledia)** Series C · FR · FinSMEs **$36M** With 5 others
- **2017** 7 rounds
- **Dec** **[Hookipa](https://millionrounds.com/company/hookipa)** Series C · AT · FinSMEs **$60M** With 8 others
- **Nov** **[YmAbs](https://millionrounds.com/company/ymabs)** US · FinSMEs **$30M** With 1 other
- **Sept** **[DNA Script](https://millionrounds.com/company/dna-script)** Series A · FR · FinSMEs **$13M** With 3 others
- **Sept** **[Entasis Therapeutics](https://millionrounds.com/company/entasis-therapeutics)** Series B · US · FinSMEs **$32M** With 2 others
- **Mar** **[Antiva Biosciences](https://millionrounds.com/company/antiva-biosciences)** Series C · US · FinSMEs **$22M** With 4 others
- **Mar** **[BioClin Therapeutics](https://millionrounds.com/company/bioclin-therapeutics)** Series B · US · FinSMEs **$30M** With 3 others
- **Feb** **[Dauntless](https://millionrounds.com/company/dauntless)** Series A · US · Biocentury **$25M** With 1 other
- **2016** 1 round
- **Nov** **[Galera Therapeutics](https://millionrounds.com/company/galera-therapeutics)** US · FinSMEs **$15M** Sole investor
- **2015** 11 rounds
- **Nov** **[First Aid Shot Therapy](https://millionrounds.com/company/first-aid-shot-therapy)** Series C · US **$24M** With 4 others
- **Oct** **[Audentes Therapeutics](https://millionrounds.com/company/audentes-therapeutics)** Series C · US **$65M** With 11 others
- **Sept** **[Aclaris Therapeutics](https://millionrounds.com/company/aclaris-therapeutics)** Series C · US **$40M** With 8 others
- **Aug** **[Checkmate Pharmaceuticals](https://millionrounds.com/company/checkmate-pharmaceuticals)** Series A · US **$20M** With 1 other
- **Aug** **[Hera Therapeutics](https://millionrounds.com/company/hera-therapeutics)** Series B · US **$16M** With 1 other
- **Jul** **[Dauntless Pharmaceuticals](https://millionrounds.com/company/dauntless-pharmaceuticals)** Series A · US **$12M** Sole investor
- **Jun** **[Crocus Technology](https://millionrounds.com/company/crocus-technology)** Series E · US **$21M** With 8 others
- **Apr** **[Merus](https://millionrounds.com/company/merus)** Series C · NL **$79M** With 10 others
- **Apr** **[Edge Therapeutics](https://millionrounds.com/company/edge-therapeutics)** Series C · US **$56M** With 5 others
- **Apr** **[Natera](https://millionrounds.com/company/natera)** Series F · US **$56M** With 6 others
- **Mar** **[aTyr Pharma](https://millionrounds.com/company/atyr-pharma)** Series E · US **$76M** Sole investor
- **2014** 14 rounds
- **Dec** **[Audentes Therapeutics](https://millionrounds.com/company/audentes-therapeutics)** Series B · US **$43M** With 5 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

## The team

Named by the firm itself, on a filing, its Form ADV or its company registration **13 named**

AL **Alain Louis Azan** Shareholder i Form ADV

AF **Anand F. Mehra** Managing Member of the General Partner i Filing they signed

EH **Eric Helmut Delbridge** Director i Form ADV

GK **Garheng Kong** Executive Officer i Filing they signed

HN **Hooman No Middle Name Shahlavi** Shareholder, Secretary and Chief Legal Officer i Form ADV

JD **James Dennis Brody** Chief Compliance Officer i Form ADV

JI **James Irvin Healy** Managing Member of the General Partner i Filing they signed

LG **Lars Gosta Ekman** Board of Directors Member, Executive Partner i Form ADV

MM **Maha Mehdi Katabi** Shareholder, Director and Vice President i Form ADV

MF **Michael F. Powell** Managing Member of the General Partner i Filing they signed

NM **Nathalie Marie Auber** Shareholder, Director and Chief Financial Officer i Form ADV

SB **Sarah Bhagat** Managing Member of the GP of the GP i Filing they signed

SF **Srinivas F. Akkaraju** Managing Member of the General Partner i Filing they signed

We also hold **31** people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

## What the register says

From the firm's own filings with the SEC, which it must file accurately by law

**$5.4B** assets it manages Oct 2026

**Registered** investment adviser full reporting to the SEC

- **Legal name:** Sofinnova Investments, Inc.
- **SEC number:** CRD 160297

Funds on its Form ADV

**7** private funds, **$2.3B** in gross assets · filed Sept 2024

Venture **4** Hedge **3**

- Sofinnova Venture Partners X, L.P. *Venture* 59 investors $803M
- Sofinnova Bioequities Enhanced Master Fund, L.P. *Hedge* 18 investors $766M
- Sofinnova Venture Partners IX, L.P. *Venture* 52 investors $289M
- Sofinnova Venture Partners XI, L.P. *Venture* 51 investors $236M
- Sofinnova Bioequities Master Fund, LTD. *Hedge* 50 investors $204M
- Sofinnova Venture Partners VIII, L.P. *Venture* 41 investors $7.7M
- Sofinnova Synergy Master Fund, L.P. *Hedge* 13 investors $5.1M

Who backs their funds

## 2 LPs on record in Sofinnova Investments's funds

- **Committed:** $155M
- **Funds:** 3
- **Vintages:** 2007 to 2014

The institutions that put money into its funds, which the firm then invests in companies. Source: the pension's own report, latest Sept 2025.

- [**California State Teachers Retirement System** 2 funds *$80M*](https://millionrounds.com/fund/california-state-teachers-retirement-system) Fund Vintage Committed Sofinnova Venture Partners IX 2014 $50M Sofinnova Venture Partners VIII 2011 $30M
- [**Oregon Public Employees Retirement Fund** 2 funds *$75M*](https://millionrounds.com/fund/oregon-public-employees) Fund Vintage Committed Sofinnova Venture Partners VIII 2011 $50M Sofinnova Venture Partners VII 2007 $25M

## Exits from the portfolio

Companies it backed that were later bought or listed **28 in all**

**[ZS Pharma](https://millionrounds.com/company/zs-pharma)** Bought by [AstraZeneca](https://millionrounds.com/fund/astrazeneca) **$2.7B** Nov 2015

**[ConteXtream](https://millionrounds.com/company/contextream)** Bought by HP Software **Undisclosed** May 2015

**[Hyperion Therapeutics](https://millionrounds.com/company/hyperion-therapeutics)** Bought by Horizon Pharma **$1.1B** Mar 2015

**[Cortina Systems](https://millionrounds.com/company/cortina-systems)** Bought by INPHI **$131M** Oct 2014

**[Civitas Therapeutics](https://millionrounds.com/company/civitas-therapeutics)** Bought by Acorda Therapeutics **$525M** Sept 2014

**[Labrys Biologics](https://millionrounds.com/company/labrys-biologics)** Bought by [Teva Pharmaceutical Industries](https://millionrounds.com/fund/teva-pharmaceutical-industries) **$825M** Jun 2014

**[Aerie Pharmaceuticals](https://millionrounds.com/company/aerie-pharmaceuticals)** Listed **Undisclosed** Oct 2013

**[KXEN](https://millionrounds.com/company/kxen)** Bought by [SAP](https://millionrounds.com/fund/sap) **Undisclosed** Sept 2013

**[Trius Therapeutics](https://millionrounds.com/company/trius-therapeutics)** Bought by [Cubist Pharmaceuticals](https://millionrounds.com/fund/cubist-pharmaceuticals) **$707M** Jul 2013

**[Trius Therapeutics](https://millionrounds.com/company/trius-therapeutics)** Listed **Undisclosed** Jul 2013

**[SARcode Bioscience](https://millionrounds.com/company/sarcode-bioscience)** Bought by [Shire](https://millionrounds.com/fund/shire) **$160M** Mar 2013

**[KaloBios Pharmaceuticals](https://millionrounds.com/company/kalobios-pharmaceuticals)** Listed **Undisclosed** Jan 2013

**[NextWave Pharmaceuticals](https://millionrounds.com/company/nextwave-pharmaceuticals)** Bought by [Pfizer](https://millionrounds.com/fund/pfizer) **Undisclosed** Oct 2012

**[Laszlo Systems](https://millionrounds.com/company/laszlo-systems)** Bought by Critical Path Inc. **Undisclosed** Feb 2012

**[Intellikine](https://millionrounds.com/company/intellikine)** Bought by [Takeda Pharmaceutical](https://millionrounds.com/fund/takeda-pharmaceutical) **$310M** Dec 2011

**[Vicept Therapeutics](https://millionrounds.com/company/vicept-therapeutics)** Bought by [Allergan](https://millionrounds.com/fund/allergan) **$275M** Jul 2011

**[HeadSprout](https://millionrounds.com/company/headsprout)** Bought by Newell Rubbermaid **Undisclosed** Mar 2011

**[HelloSoft](https://millionrounds.com/company/hellosoft)** Bought by [Imagination Technologies](https://millionrounds.com/fund/imagination-technologies) **$47M** Nov 2010

**[UPEK](https://millionrounds.com/company/upek)** Bought by AuthenTec **Undisclosed** Sept 2010

**[Anthera Pharmaceuticals](https://millionrounds.com/company/anthera-pharmaceuticals)** Listed **Undisclosed** Mar 2010

The latest 20 here. An exit counts when it came after the firm's first round in the company. From historical deal records.

New fund on file

**$500M**

raised in Aug 2025

From its SEC filing, not a journalist: a firm that has just raised has money to deploy.

## The cheque

Growth Pre-seed Seed

Median round joined **$39M** the round, not its cheque Alone, median **$14M**

Led 2 of 161 rounds **1%**

- **Sole investor:** 9 rounds
- **Last cheque:** Oct 2026
- **Exits:** 28 from the portfolio

Rounds by stage said on their site

- Series B said *46*
- Series A said *32*
- Series C *30*
- Venture *25*
- Series D *16*
- Growth said *-*
- Pre-seed said *-*

Cheques by month Led Joined

Nov 2023 Oct 2026

Often in the room with

- [Canaan](https://millionrounds.com/fund/canaan-partners) 13
- [OrbiMed](https://millionrounds.com/fund/orbimed) 12
- [Novartis Venture Fund](https://millionrounds.com/fund/novartis-venture-fund) 9
- [RA Capital Management](https://millionrounds.com/fund/ra-capital-management) 9
- [Rock Springs Capital](https://millionrounds.com/fund/rock-springs-capital) 9
- [Vivo Ventures](https://millionrounds.com/fund/vivo-ventures) 9

**Pitching Sofinnova Investments?** Put them on your fundraising board with this record on the card, and follow them to hear when they write a new cheque.

Add to your CRM *→*

## Who they invest alongside

The investors most often in the same rounds as Sofinnova Investments. A count of rooms they were both in, not a relationship either has claimed.

[**Canaan** VC firm **13** rounds together](https://millionrounds.com/fund/canaan-partners)[**OrbiMed** Private equity **12** rounds together](https://millionrounds.com/fund/orbimed)[**Novartis Venture Fund** Corporate VC **9** rounds together](https://millionrounds.com/fund/novartis-venture-fund)[**RA Capital Management** Private equity **9** rounds together](https://millionrounds.com/fund/ra-capital-management)[**Rock Springs Capital** Hedge fund **9** rounds together](https://millionrounds.com/fund/rock-springs-capital)[**Vivo Ventures** VC firm **9** rounds together](https://millionrounds.com/fund/vivo-ventures)[**Domain Associates** VC firm **8** rounds together](https://millionrounds.com/fund/domain-associates)[**5AM Ventures** VC firm **7** rounds together](https://millionrounds.com/fund/5am-ventures)[**ARCH Venture Partners** VC firm **7** rounds together](https://millionrounds.com/fund/arch-venture-partners)[**Alta Partners** VC firm **7** rounds together](https://millionrounds.com/fund/alta-partners)[**Idinvest Partners** Private equity **7** rounds together](https://millionrounds.com/fund/idinvest-partners)[**Venrock** VC firm **7** rounds together](https://millionrounds.com/fund/venrock)

## Recently backed

The latest companies Sofinnova Investments put money into.

[**Star Therapeutics** $200M · Oct 2026](https://millionrounds.com/company/star-therapeutics)[**Atsena Therapeutics** $150M · Apr 2025](https://millionrounds.com/company/atsena-therapeutics)[**DNA Script** $39M · May 2019](https://millionrounds.com/company/dna-script)[**HotSpot Therapeutics** $45M · Jul 2018](https://millionrounds.com/company/hotspot-therapeutics)[**Enyo Pharma** $47M · Jun 2018](https://millionrounds.com/company/enyo-pharma)[**Crescendo** $70M · Apr 2018](https://millionrounds.com/company/crescendo)

## Mentioned on podcasts

Episodes that name Sofinnova Investments in their description, not their title.

- [Growth Investor](https://millionrounds.com/podcasts/growth-investor) 31 Aug 2022 · 19 min Top Healthcare Investor: HealthQuest’s Garheng Kong With [Garheng Kong](https://millionrounds.com/person/garheng-kong) Mentions [Duke University](https://millionrounds.com/fund/duke-university)[HealthQuest Capital](https://millionrounds.com/fund/healthquest-capital)[Intersouth Partners](https://millionrounds.com/fund/intersouth-partners) *+1* Apple PodcastsShow page

## Quick answers about Sofinnova Investments

### What does Sofinnova Investments invest in?

Sofinnova Investments invests most often at Series B and Series A (52% of the rounds on record), in sectors such as Collaboration, Consumer and Education.

### How active is Sofinnova Investments?

161 investments on record, 2 of them in the last 12 months, and it led 2. The most recent was in Oct 2026.

### What has Sofinnova Investments invested in recently?

Its most recent investments on record: Star Therapeutics (Undisclosed round, Oct 2026), City Therapeutics (Series B, Jun 2026) and Atsena Therapeutics (Series C, Apr 2025).

### How big are Sofinnova Investments's cheques?

The median round it joins is $39M.

### Does Sofinnova Investments lead rounds?

Sometimes: it led 2 of its 161 investments on record (1%).

### Where does Sofinnova Investments invest?

Most of the companies it backs are in the United States (79%) and France (10%).

### Is Sofinnova Investments investing now?

Yes: it is actively investing, with 2 investments in the last 12 months.

### Who does Sofinnova Investments invest alongside?

Most often Canaan (13 rounds together), OrbiMed (12 rounds together) and Novartis Venture Fund (9 rounds together).

## Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. [How we count](https://millionrounds.com/methodology) · [Report a correction](https://millionrounds.com/corrections?slug=sofinnova-investments) · [Is this your firm? Claim it](https://millionrounds.com/claim?org=sofinnova-investments)